Cephalon, Inc. is an international biopharmaceutical company focused on the discovery, development and marketing of products to treat sleep disorders, neurological disorders, cancer and pain.
In the United States, the Company markets three products, Provigil (modafinil) Tablets [C-IV] for treating excessive daytime sleepiness associated with narcolepsy, Actiq (oral transmucosal fentanyl citrate) [C-II] for the management of cancer pain in opioid tolerant patients, and Gabitril (tiagabine hydrochloride) for the treatment of partial seizures associated with epilepsy.
In the United Kingdom, the Company markets Provigil and five other products, including Tegretol (carbamazepine), a treatment for epilepsy, and Ritalin (methylphenidate), a treatment for attention deficit hyperactivity disorder (ADHD).
The Company also markets other products in France, Germany, Austria and Switzerland.
cephalon.com |
